The contaminant has been linked to the deaths of more than 300 children in Africa and Asia
The decision came after a study involving 3,100 children aged between 5 and 11 who were administered with the vaccine found it to be 90.7% effective in that age group, said the statement, citing the National Health Regulatory Authority.
None of the children involved in the study showed severe side effects, it said.
Bahrain will be supplied with doses from the manufacturer for the 5-11 age group from the start of 2022, it said.